Gut bacteria boost? new trial tests probiotics to help immunotherapy fight stubborn colorectal cancer
NCT ID NCT06865521
First seen Apr 23, 2026 · Last updated Jun 22, 2026 · Updated 10 times
Summary
This early-phase study tests whether adding Akkermansia probiotics to standard immunotherapy and chemotherapy can safely help patients with advanced colorectal cancer that hasn't responded to prior treatments. The trial enrolls 22 adults whose tumors are MSS/pMMR type, which typically don't respond well to immunotherapy alone. Researchers will monitor side effects and measure tumor shrinkage, as well as changes in gut bacteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Colorectal Cancer, West China Hospital
Chengdu, Sichuan, 610041, China
-
Colorectal Cancer, West China Hospital
Chengdu, Sichuan, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Akkermansia probiotics (Songke) combined with anti-PD-1 monoclonal antibody and standard treatments (chemotherapy, TKI, or bevacizumab)
What this could lead to
If it works, this could point toward a way to make immunotherapy more effective for hard-to-treat colorectal cancers.
What could go wrong
This is a very early, small (22 people) single-center trial with no control group. The probiotics may not improve outcomes, and side effects from the combination are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.